Skip to main content
ADMA
NASDAQ Life Sciences

ADMA Biologics 拒绝空头卖家指控，援引强劲的ASCENIV需求和行业标准库存

feedReported by GlobeNewswire
Sentiment info
Neutral
Importance info
8
Price
$8.3
Mkt Cap
$1.974B
52W Low
$7.21
52W High
$25.67
Market data snapshot near publication time

summarizeSummary

ADMA Biologics 发布了一份全面声明，驳斥了空头卖家 Culper Research 于 2026 年 3 月 24 日提出的指控。该公司提供了详细的数据来反驳关于通道填充、竞争定位和其免疫球蛋白产品 ASCENIV 和 BIVIGAM 的库存水平的指控。ADMA 强调了对 ASCENIV 日益增长的终端用户需求，并呈现了分销商的库存数据，显示其水平符合行业标准，从而直接解决了短报告的断言。此外，ADMA 澄清了 ASCENIV 作为免疫缺陷患者的末端治疗方案的作用，证明了其高价位和独特的市场地位。这份详细的回应是在 3 月 25 日宣布回应后发布的，可能与正式的 8-K 文件同时发布，旨在通过提供具体证据来缓解市场的混乱并恢复投资者的信心。

在该公告发布时，ADMA的交易价格为$8.30，交易所为NASDAQ，所属行业为Life Sciences，市值约为$19.7亿。 52周交易区间为$7.21至$25.67。 这则新闻被评估为中性市场情绪，重要性评分为8/10。 来源：GlobeNewswire。

show_chartPrice Chart

Share this article

Copied!

feed ADMA - Latest Insights

ADMA
Apr 15, 2026, 4:30 PM EDT
Filing Type: DEF 14A
Importance Score:
7
ADMA Biologics Details Strong 2025 Performance, Executive Compensation, and Pipeline Progress in Definitive Proxy
Sentiment: Positive
View Wiseek Article
ADMA
Mar 28, 2026, 6:18 AM EDT
Source: Access Newswire
Importance Score:
7
Law Firm Investigates ADMA Biologics for Securities Fraud After 29% Stock Plunge
Sentiment: Negative
View Wiseek Article
ADMA
Mar 27, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
8
ADMA Biologics Issues Detailed Rebuttal to Short-Seller Allegations with Supporting Data
Sentiment: Positive
View Wiseek Article
ADMA
Mar 27, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
ADMA Biologics Rejects Short-Seller Claims, Citing Strong ASCENIV Demand and Industry-Standard Inventory
Sentiment: Neutral
View Wiseek Article
ADMA
Mar 25, 2026, 6:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Misleading Short-Seller Report Allegations Rebutted by ADMA Biologics
Sentiment: Negative
View Wiseek Article
ADMA
Mar 02, 2026, 7:13 AM EST
Source: Unknown
Importance Score:
8
ADMA Biologics Launches $125M Accelerated Share Repurchase, Part of ~$200M 2026 Buyback Plan
Sentiment: Positive
View Wiseek Article
ADMA
Mar 02, 2026, 7:05 AM EST
Filing Type: 8-K
Importance Score:
9
ADMA Biologics Launches $125M Accelerated Share Repurchase, Part of $200M 2026 Capital Return Plan
Sentiment: Positive
View Wiseek Article
ADMA
Feb 25, 2026, 5:16 PM EST
Filing Type: 10-K
Importance Score:
8
ADMA Biologics Reports Record 2025 Financials, Driven by ASCENIV Growth and Strategic Initiatives
Sentiment: Positive
View Wiseek Article
ADMA
Feb 25, 2026, 4:11 PM EST
Filing Type: 8-K
Importance Score:
8
ADMA Biologics Reports Record 2025 Financial Results, Strong 2026-2029 Guidance, and Smooth CFO Transition
Sentiment: Positive
View Wiseek Article
ADMA
Jan 12, 2026, 8:20 AM EST
Filing Type: 8-K
Importance Score:
8
ADMA Biologics Raises 2026 Guidance, Projects Strong Long-Term Growth to $1.1B Revenue by 2029
Sentiment: Positive
View Wiseek Article